Document:

EX-10.19

 Exhibit 10.19 

 
 

 
 Organon Executive Severance Program 

This document sets forth the terms of the Organon Executive Severance Program (as the same may be amended, the “Plan”) as in effect on
June 2, 2021. This document is both the legal plan document as well as the Summary Plan Description for the Plan. 
 The Plan applies to certain
executives of Organon & Co. and its wholly owned subsidiaries who are determined to be participants in the Plan. 
 Organon reserves the right to
amend, modify or terminate the Plan in whole or in part or to discontinue the Plan completely at any time. 
 Terms that are frequently used in the Plan are
defined in the Glossary. 
  

 Contents 
  

					
	 About Your Executive Severance Program
	  			
		
	 Overview
	  	 	1	 
	 Eligibility
	  	 	1	 
	 Eligibility in General
	  	 	1	 
	 When Eligibility Ends
	  	 	1	 
	 ERISA
	  	 	2	 
	 Receive Information About Your Plan and Benefits
	  	 	2	 
	 Prudent Actions by Plan Fiduciaries
	  	 	2	 
	 Enforce Your Rights
	  	 	2	 
	 Assistance with Your Questions
	  	 	3	 
	 Administrative Information
	  	 	3	 
	 Sponsor
	  	 	4	 
	 Plan Administrator
	  	 	4	 
	 Agent for Service of Legal Process
	  	 	5	 
	 Plan Funding and Administration
	  	 	5	 
	 No Right to Employment
	  	 	6	 
	 Plan Amendment and Termination
	  	 	6	 
	 Plan Year
	  	 	6	 
		
	 Benefits under the Executive Severance Program
	  			
		
	 How the Plan Works
	  	 	7	 
	 Termination without Cause
	  	 	7	 
	 Separation Pay Schedule
	  	 	7	 
	 Continuation of Medical and Dental Coverage
	  	 	7	 
	 Continuation of Basic Life Insurance Coverage
	  	 	9	 
	 Outplacement Benefits
	  	 	9	 
	 Reduction of Benefits
	  	 	9	 
	 When and How Benefits Are Paid
	  	 	10	 
	 Taxation of Benefits
	  	 	10	 
	 Forfeiture of Benefits
	  	 	10	 
	 Cessation of Separation Pay and Benefits
	  	 	11	 
	 Return of Separation Pay
	  	 	11	 
	 Death of Participant
	  	 	12	 
	 Filing a Claim
	  	 	12	 
	 Appealing An Adverse Benefit Determination
	  	 	13	 
		
	 Glossary
	  	 	15	 

  

					
	 Organon Executive Severance
 Program
	  	i	  	Effective: June 2, 2021

  

About Your Executive Severance Program 
 The following
About Your Executive Severance Program section provides you with important information about eligibility and other administrative details. 

Overview 
 This Plan is designed to help you meet
financial needs if your employment with the Employer is terminated under certain circumstances. 
 Eligibility 

Eligibility in General 
 Termination without
Cause. You will be eligible to receive Separation Pay, Separation Benefits and Outplacement Benefits under this Plan if you are an Eligible Employee whose employment with the Employer terminates in a Qualifying Termination as a result of
your termination by the Employer without Cause (and not as the result of your performance). Such benefits are provided only if you have signed and, if a revocation period is applicable, not revoked, a Release of Claims. 

Release of Claims. The Release of Claims will contain such terms and conditions as determined by the Employer, including but not limited to a
general release of claims, known or unknown, that you may have against the Employer and its affiliates, including claims related to your employment and termination of employment. Such Release of Claims may also contain, in the Employer’s
discretion, other terms and conditions including, without limitation, post-termination cooperation, non-disclosure, confidentiality, non-disparagement, non-solicitation and/or non-competition provisions. 
 Eligible
Employee. An Eligible Employee under this Plan includes employees of an Employer in Band 700 or higher. However, any employee of an Employer who has an individual employment, separation or similar agreement with the Employer that provides
for separation, severance or termination payments or benefits will not be eligible for Separation Plan Benefits under this Plan, but rather the terms of such individual employment, separation or similar agreement will control. In addition, should
benefits be payable to a participant in the Organon Executive Change in Control Severance Plan, no payments or benefits will be provided under this Plan. 

See the Glossary for the full definition of Eligible Employee, Qualifying Termination and Release of Claims. 

When Eligibility Ends 
 Your eligibility to participate in
this Plan ends on the earliest of: 

  

					
	 Organon
 Executive Severance Program
	  	1	  	Effective: June 2, 2021

	 	•	 	 The date your employment with the Employer terminates for any reason other than a Qualifying Termination;

  

	 	•	 	 The date you are no longer an Eligible Employee; or 

 

	 	•	 	 The date this Plan is terminated by the Employer. 

ERISA 
 This Plan is considered a “welfare benefit
plan” under the Employee Retirement Income Security Act of 1974, as amended (ERISA). You are entitled to certain rights and protections under ERISA. ERISA provides that all plan participants are entitled to: 

Receive Information About Your Plan and Benefits 
  

	 	•	 	 Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as
worksites and union halls, all documents governing this Plan. 

  

	 	•	 	 Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of this Plan
and updated summary plan descriptions. The Plan Administrator may make a reasonable charge for the copies. 

 Prudent Actions by Plan
Fiduciaries 
 In addition to creating rights for plan participants, ERISA imposes duties upon the people who are responsible for the operation of the
employee benefit plan. The people who operate the Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of you and other plan participants and beneficiaries. No one, including your employer, or any
other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your rights under ERISA. 

Enforce Your Rights 
 If your claim for a welfare benefit
is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. See Filing a Claim and
Appealing a Claim. 
 Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of plan documents or
the latest annual report from the Plan (if applicable) and do not receive them within 30 days, you may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day
until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. 

  

					
	 Organon
 Executive Severance Program
	  	2	  	Effective: June 2, 2021

 If you submit a claim for benefits under this Plan within the time period specified for filing a claim and
your claim is: 
  

	 	(i)	 ignored, or 

  

	 	(ii)	 denied, and you file an appeal within the applicable time frame and that appeal is then 

 

	 	(a)	 ignored or 

  

	 	(b)	 denied, 

you may file a lawsuit in a state or Federal court. Please note that before you can file a lawsuit in a state or Federal court, you must follow the
Plan’s procedures for filing a claim and an appeal of a denied claim. 
 If it should happen that the plan fiduciaries misuse the Plan’s money, or
if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file a lawsuit in a Federal court. If you file a lawsuit the court will decide who should pay court costs and legal
fees. If you are successful the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous. 

Assistance with Your Questions 
 If you have any questions
about this Plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest
office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or write to the following address: 

Division of Technical Assistance and Inquiries 

Employee Benefits Security Administration 

U.S. Department of Labor 
 200
Constitution Avenue, N.W. 
 Washington, DC 20210 

You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits
Security Administration or visiting their website. 
 Administrative Information 

This section contains information on the administration and funding for this Plan. While you may not need this information for
day-to-day participation in this Plan, you should read through this section. It is important for you to understand your rights, the procedures you need to follow, and
the appropriate contacts you may need in certain situations. 

  

					
	 Organon
 Executive Severance Program
	  	3	  	Effective: June 2, 2021

 Sponsor 

Organon LLC sponsors this Plan. The employer identification number assigned to Organon LLC by the IRS is #85-2269702.
The address and phone number for Organon LLC is as follows: 
 Secretary, Total Rewards Operations Council 

Organon LLC 
 30 Hudson Street

 Jersey City, NJ 07302 
 1-215-631-6972 
 Plan Administrator

 The Plan Administrator for this Plan is Organon’s Total Rewards Operations Council or its delegate; provided, however, that the Talent Committee
of the Board of Directors of Organon & Co. (the “Board”) administers this Plan with respect to any executive officers of Organon & Co. other than the Chief Executive Officer of Organon & Co. and the Board
administers this Plan with respect to the Chief Executive Officer of Organon & Co. Any references to Organon’s “Total Rewards Operations Council” will refer to the Talent Committee or the Board with respect to such
Participants. Administration of this Plan is the responsibility of the Plan Administrator. The Plan Administrator makes determinations as to eligibility and benefits. 

The Plan Administrator has the full exclusive discretionary authority to: 
  

	 	•	 	 Construe and interpret the provisions of this Plan (including without limitation, supplying omissions from,
correcting deficiencies in, or resolving inconsistencies or ambiguities in, the language of this Plan); 

  

	 	•	 	 Determine all questions of fact arising under this Plan; 

 

	 	•	 	 Decide all questions of eligibility for benefits; 

 

	 	•	 	 Determine the amount of benefits; 

 

	 	•	 	 Establish such rules and regulations (consistent with the terms of this Plan) as it deems necessary or
appropriate for administration of this Plan; 

  

	 	•	 	 Delegate responsibilities to others to assist in administration of the Plan; and 

 

	 	•	 	 Perform all other acts it believes reasonable and proper in connection with the administration of this Plan.

 Its decisions on such matters are final and conclusive. The Plan Administrator has reserved the right to delegate all or any portion of
its discretionary authority described in the preceding sentence to a representative and the representative’s decisions on such matters are final and conclusive. With respect to determining claims and appeals for benefits under this Plan, the
Claims Reviewer (and its delegate) is the delegate of the Plan Administrator and has all of the powers and duties of the Plan Administrator described above. 

  

					
	 Organon
 Executive Severance Program
	  	4	  	Effective: June 2, 2021

 Any interpretations or determinations made pursuant to such discretionary authority of the Plan
Administrator or its representative will be upheld in judicial review unless it is shown that the interpretation or determination was an abuse of discretion. 

If you have any questions concerning this Plan, please contact the Plan Administrator as follows: 

Chief Human Resources Officer 

Organon & Co. 
 30
Hudson Street 
 Jersey City, NJ 07302 

Agent for Service of Legal Process 
 If, for any reason,
you want to seek legal action against this Plan, you can serve legal process on Organon, by directing service to the following address: 

General Counsel 

Organon & Co. 
 30
Hudson Street 
 Jersey City, NJ 07302 

Plan Funding and Administration 
 Separation Pay and
Outplacement Benefits under this Plan are financed entirely by the Employer, are paid from the Employer’s general assets as due and constitute an unfunded obligation of the Employer. This Plan constitutes solely an unsecured promise by the
Employer to pay the benefits to Participants to the extent provided herein. Participant contributions are required for the continued medical and dental benefits which are part of the Separation Benefits. Separation Benefits under this Plan provide
Participants with eligibility for continued medical and dental and life insurance coverage under the applicable plans of Employer or its subsidiaries. This Plan does not provide the substantive benefits under those plans. For information on the
funding and administration of each of those plans, see the summary plan descriptions (and any applicable summaries of material modification) applicable to each individual plan. 

This Plan is not intended to be an “employee pension plan” as the term is defined in section 3(2) of ERISA. The Plan is, however, intended to be an
employee welfare benefit plan as the term is defined in section 3(1) of ERISA. 
 This Plan and all rights thereunder are to be governed by and construed in
accordance with ERISA and, to the extent not preempted by Federal law, with the laws of the state of Delaware, wherein venue shall lie for any dispute arising hereunder. 

  

					
	 Organon
 Executive Severance Program
	  	5	  	Effective: June 2, 2021

											
	 Plan Funding and Administration
Chart

	 Formal Plan Name
	  	 Plan Number
	  	 Plan/Type Benefits
Type
	  	 Plan Administrator
	  	 Type of
Administration
	  	 Insured or Self-
insured

	Organon Executive Severance Program	  	514	  	Welfare/ Severance	  	Organon Total Rewards Operations Council	  	Employer Administration	  	Self-insured by the Employer

 No Right to Employment 

Nothing in this Plan represents nor is considered an employment contract, and neither the existence of this Plan nor any statements made by or on behalf of the
Employer can be construed to create any promise or contractual right to employment or to the benefits of employment. Subject to the requirements of applicable law, the Employer or you may terminate the employment relationship without notice at any
time and for any reason. 
 Plan Amendment and Termination 

The Total Rewards Strategic Design Council has the right to amend, modify or terminate this Plan at any time without prior notice to or the consent of any
employee; provided, however, that any such action that affects benefits payable hereunder to the Chief Executive Officer shall be approved by the Board and any such action that affects any other executive officer of the Organon & Co. shall
be approved by the Talent Committee of the Board. 
 Notwithstanding the foregoing, for two years following a Change in Control, the material terms of this
Plan (including terms relating to eligibility, benefit calculation, benefit accrual, cost to participants, subsidies and rates of employee contributions) may not be modified in a manner that is materially adverse to Eligible Employees. During that two-year period, the Employer will pay the legal fees and expenses of any Eligible Employee that prevails on at least one material item of his or her claim for relief in an action regarding an impermissible
amendment (other than ordinary claims for benefits). 
 Any Eligible Employee whose employment continues after amendment of this Plan is governed by the
Plan as so amended. Any Eligible Employee whose employment continues after termination of this Plan has no right to Separation Plan Benefits. Nothing in this Plan in any way limits the right of the Employer (or its applicable subsidiary) to amend or
terminate any or all of the plans of the Employer (or its applicable subsidiary) that provide Separation Benefits under this Plan. 
 Plan Year 

The plan year for this Plan ends on December 31 of each year. The financial records of this Plan are kept on a calendar-year basis. 

  

					
	 Organon
 Executive Severance Program
	  	6	  	Effective: June 2, 2021

  

Benefits under the Executive Severance Program 
 How the
Plan Works 
 Termination without Cause 
 You may
receive Separation Pay, Separation Benefits and Outplacement Benefits under this Plan if your employment is terminated by the Employer without Cause (and not as the result of your performance). Such benefits are provided only if you have signed,
and, if a revocation period is applicable, not revoked, a Release of Claims. If you meet all these conditions for eligibility, you are considered a Participant in the Plan. 

Separation Pay Schedule 
 Upon a Qualifying Termination,
your Separation Pay under this Plan includes: 
  

	 	(i)	 a lump sum cash severance payment in an amount equal to the sum of your Annual Base Salary (the “Base
Salary Separation Pay”) and your Annual Target Bonus; provided, however, if you are the Chief Executive Officer of Organon & Co. such payment shall be equal to the sum of two times (2x) your Annual Base Salary and two times (2x)
your Annual Target Bonus; and 

  

	 	(ii)	 if your employment is terminated between June 30th and
December 31st of the calendar year, a pro-rata Annual Target Bonus for the calendar year in which your termination of employment occurs, calculated based on
the AIP-Eligible Months that you were employed during the year. 

 Notwithstanding
the foregoing, if you were employed by Merck & Co., Inc. or any of its direct or indirect wholly-owned subsidiaries immediately prior to the legal separation of Organon & Co. and Merck & Co, Inc., the Base Salary
Separation Pay component of your Separation Pay shall be no less than the amount calculated in Exhibit A (based on your complete years of continuous service with the Employer and Merck & Co., Inc. and its wholly-owned subsidiaries to
the extent recognized by Merck & Co., Inc. and its subsidiaries immediately prior to legal separation of Organon & Co. and Merck & Co, Inc.). For purposes of this Plan, years of continuous service will be calculated from
your most recent re-hire date. 
 Continuation of Medical and Dental Coverage 

A Participant who is covered under any of the Employer’s group employee medical and dental plans as of his or her Separation Date will be provided the
opportunity to continue his or her employee and dependent coverage during his or her Benefits Continuation Period (as such coverage may be amended from time to time, in accordance with the terms and conditions of such plans), provided the
Participant timely pays the required contribution to continue coverage. 

  

					
	 Organon
 Executive Severance Program
	  	7	  	Effective: June 2, 2021

 
The required contribution is calculated at the active employee rates applicable to such coverage, as the same may be changed from time to time, during his or her Benefits Continuation Period.

 A Participant who, prior to his or her Separation Date, had elected no employee medical or dental coverage under the applicable employee medical or
dental plan will not be permitted to change from no medical and/or dental coverage to coverage as a result of a Qualifying Termination. 
 The Benefits
Continuation Period begins on the first day of the month following the Participant’s Separation Date and shall end on the last day of the month in which the Benefits Continuation Period ends, provided the Participant pays the required
contributions for coverage in the time and manner required. If the Participant fails to pay the required contributions for coverage in the time and manner required, or the Participant elects to terminate active medical and/or dental coverage,
coverage will end as of the last day of the month for which the contribution was paid and it will not be reinstated during the Benefits Continuation Period. If the Participant has medical and/or dental coverage on the last day of the Benefits
Continuation Period, the Participant may be eligible to continue coverage in effect at the end of the Benefits Continuation Period in accordance with COBRA or other similar law by timely electing and paying the full COBRA, or other applicable,
premium. 
 If the Participant elects to end the Benefits Continuation Period earlier than the period set forth in the definition of the Benefits
Continuation Period, all employee medical and/or dental benefit coverage that the Participant would otherwise have been eligible to receive during the maximum Benefits Continuation Period will be permanently and irrevocably forfeited. 

If, as of his or her Separation Date, a Participant is eligible to participate in the Merck Retiree Medical Plan, then he or she: 

 

	 	•	 	 will be eligible to continue active Organon medical and dental benefits during the Benefits Continuation Period
as described above; and 

  

	 	•	 	 following the completion of the Benefits Continuation Period, will be eligible for retiree medical benefits in
accordance with the terms of the Merck Retiree Medical Plan, as it may be amended from time to time. 

 If a Participant is not eligible to
continue Organon employee medical coverage during the Benefits Continuation Period (i.e., because the Participant had no employee coverage on his/her Separation Date) or the Participant’s medical coverage ends during the Benefits Continuation
Period (for any reason, including non-payment), the Participant cannot enroll for Merck Retiree Medical Plan coverage until the end of the Benefits Continuation Period. If the Participant elects to end the
Benefits Continuation Period earlier than the period set forth on Exhibit B, all Organon employee medical and/or dental benefit coverage that the Participant would otherwise have been eligible to receive during the maximum Benefits Continuation
Period will be permanently and irrevocably forfeited. A Participant cannot be covered as an Organon employee and as a Merck retiree (even under the retiree no coverage option, if available) during the same period; provided, however, that a
Participant may be covered through COBRA at full COBRA rates for Organon employee dental coverage even if during that period the Participant is also covered as a Merck retiree for medical coverage. 

  

					
	 Organon
 Executive Severance Program
	  	8	  	Effective: June 2, 2021

 Continuation of Basic Life Insurance Coverage 

A Participant will be eligible to continue Basic Life Insurance coverage at no cost to the Participant during his or her Benefits Continuation Period subject
to and in accordance with the terms of the applicable life insurance plan as they may be amended from time to time. The Participant is responsible for paying applicable tax on imputed income, if any, for Basic Life Insurance coverage during his or
her Benefits Continuation Period. 
 Outplacement Benefits 

A participant will be eligible for 12 months of outplacement counseling or other outplacement services. Outplacement Benefits are provided through a third
party vendor. The Employer reserves the right to change the vendor or the programs at any time. 
 Reduction of Benefits 

Notwithstanding anything in this Plan to the contrary, a Participant’s Separation Pay and Separation Benefits, if applicable, will be reduced by: 

 

	 	•	 	 Any amount the Plan Administrator reasonably concludes the Participant owes the Employer including, without
limitation, unpaid bills under the corporate credit card program and for vacation used, but not earned; 

  

	 	•	 	 Any severance or severance-type benefits that the Employer must pay to a Participant under applicable law or
collective or labor agreement (other than unemployment compensation under applicable law), including any amounts payable pursuant to the Worker Adjustment and Retraining Notification Act (“WARN”) or any other similar federal, state or
local statute; 

  

	 	•	 	 Where permitted by law, any payments received by the Participant pursuant to state workers compensation laws; and

  

	 	•	 	 Short-term disability benefits where applicable law does not permit Separation Pay to be offset from short term
disability benefits (or where the Employer in its sole and absolute discretion determines it is administratively easier for the Employer to reduce Separation Pay by short term disability benefits in lieu of reducing short term disability benefits by
Separation Pay). 

  

					
	 Organon
 Executive Severance Program
	  	9	  	Effective: June 2, 2021

 When and How Benefits Are Paid 

Separation Pay will be paid in a lump sum (less applicable withholdings) as soon as practicable after the Participant’s Separation Date and the expiration
of any period during which the Participant may consider, sign and, if a revocation period is applicable, revoke the Release of Claims, but in no event later than March 15 of the calendar year following the Participant’s Separation Date. If
the period during which the Participant may consider, sign and, if a revocation period is applicable, revoke, the Release of Claims spans two calendar years the Separation Pay will be paid in the second calendar year. 

Notwithstanding anything in this Plan to the contrary, benefits under this Plan (including Separation Pay and Separation Benefits) that are subject to
Section 409A of the Code, will be administered to comply with and to avoid the excise tax under Section 409A. The Employer will take any and all steps it determines are necessary, in its sole and absolute discretion, to adjust benefits
under this Plan (including Separation Pay and Separation Benefits) to avoid the excise tax under Section 409A, including but not limited to, reducing or eliminating benefits, changing the time or form of payment of benefits, etc. 

Notwithstanding anything contained in this Plan to the contrary, if a Participant is a “Specified Employee” (as defined under Section 409A) on
his or her Separation Date, to the extent required by Section 409A, no payments will be made to him or her until the earlier of (i) his or her death; or (2) the expiration of the six-month
period following his or her Separation Date. Instead, amounts that would otherwise have been payable during that six-month period will be accumulated and paid, without interest, as soon as administratively
feasible, and in all events within 30 days, following the end of such six-month period. 
 Taxation of Benefits

 Separation Pay is subject to the withholding of appropriate Federal, state and local taxes. The Employer will withhold taxes as required, but the
Employer reserves the right to treat Separation Pay as supplemental wages subject to flat-rate withholding (not taking into account any exemptions). 
 In
the event that any payments or benefits provided or to be provided by the Employer or its affiliates for the benefit of the Participant, whether paid or payable pursuant to this Plan or otherwise, constitute parachute payments within the meaning of
Section 280G of the Code and would be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then such payments or benefits shall be reduced to the minimum extent necessary to avoid the imposition of
the Excise Tax, but only if such reduction would cause the amount to be retained by the Participant to be greater than would be the case if the Participant were required to pay the Excise Tax. Any such reduction shall be made by the Employer in its
sole discretion consistent with the requirements of Section 409A of the Code. 
 Forfeiture of Benefits 

The Employer reserves the right, in its sole and absolute discretion, to cancel all Separation Plan Benefits and to seek the return of Separation Pay in the
event a Participant engages in any activity that the Employer considers detrimental to its interests (or the interests of any of its affiliates) as determined by Organon’s Total Rewards Operations Council. Activities that the Employer considers
detrimental to its interest (or the interests of any of its subsidiaries or affiliates) include, but are not limited to: 

  

					
	 Organon
 Executive Severance Program
	  	10	  	Effective: June 2, 2021

	 	•	 	 Any activity that constitutes Cause (regardless of whether such activity is known before or after the Eligible
Employee’s Separation Date, unless the Claims Reviewer determines in its sole discretion that Cause shall not cause the forfeiture of Separation Plan Benefits in a particular case); 

 

	 	•	 	 Breach of any obligations of the Participant’s terms and conditions of employment; 

 

	 	•	 	 Making false or misleading statements about the Employer or any of its affiliates or their products, officers or
employees to competitors, customers, potential customers or to current employees or former employees of the Employer; and 

  

	 	•	 	 Breaching any of the terms of the Release of Claims, including, if included in the Release of Claims, any non-solicitation or non-competition provisions. 

 Cessation
of Separation Pay and Benefits 
 Separation Pay and Separation Benefits cease in the event a Participant is rehired by the Employer or one of its
affiliates. 
 A Participant shall cease to participate in the Plan, and all Separation Plan Benefits shall cease upon the occurrence of the earliest of:

  

	 	•	 	 Termination of the Plan; 

 

	 	•	 	 Inability of the Employer to pay Separation Plan Benefits when due; 

 

	 	•	 	 Completion of payment to the Participant of the Separation Plan Benefits for which the Participant is eligible;
and 

  

	 	•	 	 The Claims Reviewer’s determination, in its sole discretion, of the occurrence by the Eligible Employee of
an activity that constitutes Cause, regardless of whether such determination occurs before or after the Eligible Employee’s Separation Date, unless the Claims Reviewer determines in its sole discretion that Cause shall not cause the cessation
of Separation Plan Benefits in a particular case. 

 Return of Separation Pay 

If an event occurs pursuant to which Separation Plan Benefits would cease or otherwise be reduced or offset (see Reduction of Benefits, Forfeiture of
Benefits and Cessation of Separation Pay and Benefits), then, to the fullest extent permitted by applicable law, the Participant must repay to the Employer the gross amount of any Separation Plan Benefits previously paid or provided
within thirty (30) days following receipt of a demand for such repayment. 

  

					
	 Organon
 Executive Severance Program
	  	11	  	Effective: June 2, 2021

 Death of Participant 

If a Participant dies following his or her Separation Date and a valid Release of Claims was signed by the Participant or is signed by the Participant’s
estate then: 
  

	 	•	 	 any unpaid Separation Pay will be paid to the Participant’s estate; and 

 

	 	•	 	 if the Participant was eligible to continue medical and/or dental coverage during the Benefits Continuation
Period on the Participant’s date of death and the Participant’s surviving dependents were covered under the Participant’s medical and dental coverages at the time of the Participant’s death, they may continue such coverage
for the balance of the Benefits Continuation Period, provided they continue to remain eligible dependents and they pay the applicable contributions at active employee rates, as they may change from time to time. 

Medical and dental coverage under this section is subject to and in accordance with the terms of the applicable plans of Employer (or its
subsidiaries) as they may be amended from time to time. 
 Filing a Claim 

If benefits are not automatically paid or provided to you and you feel you are entitled to benefits under this Plan or if you have a dispute regarding a
benefit paid or provided, you (or your duly authorized representative) must file a claim with the Claims Reviewer at the following address: 

Total Rewards Operations Council 

Organon LLC 
 30 Hudson Street

 Jersey City, NJ 07302 
 Your claim must be
received by the Claims Reviewer within 60 days after your employment with an Employer ends; provided, however for claims regarding the cessation of Separation Plan Benefits, the claim must be received by the Claims Reviewer within 60 days after the
date Separation Plan Benefits are cancelled. 
 The claim for benefits will be reviewed by, and a determination made by, the Claims Reviewer. The Claims
Reviewer will make a determination regarding the claim within a reasonable time, but not later than 90 days after its receipt by the Claims Reviewer. If the Claims Reviewer determines that an extension of time to process the claim is required, you
will receive written notice before the end of the initial 90-day period indicating the special circumstances requiring an extension (not to exceed an additional 90 days without your written consent) and the
date by which the Claims Reviewer expects to render a decision. 
 If the Claims Reviewer does not fully agree with your claim, you will receive a written
or electronic notice of an “adverse benefit determination” within the 90-day period (as it may be extended as described above). The notice of adverse benefit determination will include: 

  

					
	 Organon
 Executive Severance Program
	  	12	  	Effective: June 2, 2021

	 	•	 	 The specific reason(s) for the adverse benefit determination; 

 

	 	•	 	 The specific provision(s) of this Plan on which the determination was based; 

 

	 	•	 	 Any material or information necessary for the benefits to be paid or provided as well as an explanation of why
the material or information is necessary; 

  

	 	•	 	 An explanation of the appeal procedures set forth below; and 

 

	 	•	 	 A statement of your right to bring a civil action under section 502(a) of ERISA following the denial of your
appeal. 

 An “adverse benefit determination” is a denial, reduction, or termination of, or failure to provide, or make payment
(in whole or in part) of a benefit. 
 With respect to Separation Benefits, the claims and appeals procedure described in this Plan apply only to claims for
eligibility to continue participation in medical, dental and life insurance coverage due to a Qualifying Termination under the applicable plans of Employer. Claims and appeals for substantive benefits (e.g., payment of medical/dental or life
insurance claims incurred) under those plans must be filed in accordance with the applicable provisions of those plans. 
 Appealing An Adverse Benefit
Determination 
 If you receive notice of an adverse benefit determination, you are entitled to apply for a full and fair review of your claim and the
adverse benefit determination. To apply for the a review, you or your duly authorized representative must file an appeal within 60 days after your receipt of the Claims Reviewer’s notice of adverse benefit determination. If you fail to file a
written appeal within the 60-day period, the Claim Reviewer’s adverse benefit determination is final and conclusive. 

The appeal must be made in writing and must be filed with the Plan Administrator within the 60-day period at the
following address: 
 Total Rewards Operations Council 

Organon LLC 
 30 Hudson Street

 Jersey City, NJ 07302 
 The appeal is
deemed to be filed when it is received by the Total Rewards Operations Council. 
 You or your duly authorized representative may upon request and free of
charge have reasonable access to, and copies of, all documents, records and other information relevant (the relevance to be determined by the Total Rewards Operations Council in accordance with ERISA) to your claim for benefits and may submit in
writing any comments, documents, records and other information relating to your claim for benefits. The Total Rewards Operations Council will re-examine all issues relevant to the original adverse benefit
determination taking into account all comments, document, records and other information submitted by you or your duly authorized representative relating to the claim without regard to whether the information was submitted or considered in the
initial benefit determination. 

  

					
	 Organon
 Executive Severance Program
	  	13	  	Effective: June 2, 2021

 The Total Rewards Operations Council will provide written or electronic notice to you or your duly
authorized representative of its determination on review. The notice will be provided within a reasonable time, but not later than 60 days after the appeal is received by the Total Rewards Operations Council. If the Total Rewards Operations Council
determines that an extension of time to process the claim is required, you will receive written notice before the end of the initial 60-day period indicating the special circumstances requiring an extension
(not to exceed an additional 60 days without your written consent), and the date by which the Total Rewards Operations Council expects to render a decision. 

If your appeal is denied, you will receive a notice of adverse benefit determination on review. The notice will include: 

 

	 	•	 	 The specific reason(s) for the adverse determination on review; 

 

	 	•	 	 Reference to the specific provisions of the Executive Severance Program on which the benefit determination is
based; 

  

	 	•	 	 A statement that you are entitled to receive, upon request and free of charge, reasonable access to, and copies
of, all documents, records, and other information relevant to the claim for benefits (the relevance to be determined by the Total Rewards Operations Council in accordance with ERISA); and 

 

	 	•	 	 A description of your right to bring a civil action under Section 502(a) of ERISA following an adverse
benefit determination on review. 

 All decisions of the Total Rewards Operations Council are final and binding unless determined to be
arbitrary and capricious by a court of competent jurisdiction. 

  

					
	 Organon
 Executive Severance Program
	  	14	  	Effective: June 2, 2021

  

Glossary 
 Glossary Terms 

“AIP-Eligible Months” means the number of days that a Participant was employed in a position that was
eligible to participate in the Employer’s annual bonus program during the Plan Year adjusted for any leaves of absence and divided by 30, with regular rounding rules applied. 

“Annual Base Salary” means a Participant’s annual base salary as in effect at his or her Separation Date, according to the
Employer’s payroll records, without reduction for any contributions to Employer-sponsored benefit plans. Annual Base Salary does not include bonuses, commissions, overtime pay, shift pay, premium pay, lump sum merit increases, cost of living
allowances, income from stock options or other incentives under an incentive stock plan of the Employer, stock grants or other incentives, or other pay not specifically included above. 

“Annual Target Bonus” means a Participant’s annual target bonus opportunity as in effect at his or her Separation Date under the
annual bonus plan or program maintained by the Employer. 
 “Basic Life Insurance” means life insurance provided to an Eligible Employee
under a plan sponsored by the Employer equal to 1.0 x “base pay” as defined under the life insurance plan in which the Eligible Employee participates, as it may be amended from time to time. 

“Benefits Continuation Period” means twelve (12) months following the first day of the calendar month following the Eligible
Employee’s Separation Date; provided, however, if the Eligible Employee is the Chief Executive Officer of Organon & Co. such period shall be twenty-four (24) months following the first day of the calendar month following the
Eligible Employee’s Separation Date. 
 Notwithstanding the foregoing, if you were employed by Merck & Co., Inc. or any of its direct or
indirect wholly-owned subsidiaries immediately prior to the legal separation of Organon & Co. and Merck & Co, Inc and have 20 or more complete years of continuous service (based on your complete years of continuous service with the
Employer and Merck & Co., Inc. and its wholly-owned subsidiaries to the extent recognized by Merck & Co., Inc. and its subsidiaries immediately prior to legal separation of Organon & Co. and Merck & Co, Inc.),
such period shall be 78 weeks following the first day of the calendar month following the Eligible Employee’s Separation Date (or through the last day of the month in which such 78-week period ends if the
Eligible Employee is eligible for subsidized retiree medical benefits under the Merck Retiree Medical Plan on their Separation Date). 

  

					
	 Organon
 Executive Severance Program
	  	15	  	Effective: June 2, 2021

 Glossary Terms 

“Cause” means a Participant’s: (i) material breach of any written agreement between the Participant and the Employer,
including the Participant’s breach of any material representation, warranty or covenant made under any such agreement, or the Participant’s breach of any written policy or code of conduct established by the Employer and applicable to
Participant; (ii) commission of an act of gross negligence, willful misconduct, breach of fiduciary duty, fraud, theft or embezzlement; (iii) commission of, or conviction or indictment for, or plea of nolo contendere to, any felony (or
state law equivalent) or any crime involving moral turpitude; or (iv) willful failure or refusal to perform Participant’s duties to the Employer or to follow any lawful directive from the Board or Participant’s supervisor. 

“Claims Reviewer” means Organon’s Total Rewards Operations Council or its delegate. 

“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, Section 4980B of the Code, and Section 601, et
seq., of ERISA. 
 “Code” means the Internal Revenue Code of 1986, as amended. 

“Eligible Employee” means any regular full-time or regular part-time employee of an Employer who is in Band 700 or higher excluding
any employee who has an individual employment, separation or similar agreement with the Employer that provides for separation, severance or termination payments or benefits. An “Eligible Employee” does not include any individual who is
considered by the Employer in its sole discretion to be an independent contractor, regardless of whether the individual is in fact an employee of the Employer. 

Whether an individual is an Eligible Employee or not is determined as of the date of his/her Qualifying Termination. 

“Employer” means Organon & Co. and its subsidiaries, successors and assigns who participate in this Plan by virtue of
employing an Eligible Employee. 
 “Outplacement Benefits” means benefits for outplacement counseling or other outplacement services made
available to a Participant who incurs a Qualifying Termination described in the Outplacement Benefits section of this Plan. 

“Participant” means an Eligible Employee who has experienced a Qualifying Termination and who has signed, and, if a revocation period
is applicable, not revoked, a Release of Claims in a form that is satisfactory to the Employer in its sole and absolute discretion. 

“Plan” means this Organon Executive Severance Program, as it may be amended from time to time. 

“Plan Administrator” means the Total Rewards Operations Council or its delegate. 

“Plan Year” means the calendar year January 1 through December 31 on which the records of the Plan are kept. 

  

					
	 Organon
 Executive Severance Program
	  	16	  	Effective: June 2, 2021

 Glossary Terms 

“Qualifying Termination” means the termination of an Eligible Employee’s employment by the Employer without Cause (and not as the result
of the Eligible Employee’s performance). The determination of whether a termination of an Eligible Employee’s employment by the Employer is a Qualifying Termination and was not the result of the Eligible Employee’s performance shall
be made in the sole discretion of the Employer. 
 “Release of Claims” means the agreement that an Eligible Employee must execute in
order to become a Participant and to receive Separation Plan Benefits, which shall be prepared by the Employer and shall contain such terms and conditions as determined by the Employer, including but not limited to a general release of claims, known
or unknown, that the Eligible Employee may have against the Employer and its affiliates, including claims related to the employment and termination of employment of the Eligible Employee. Such Release of Claims may also contain, in the
Employer’s discretion, other terms and conditions including, without limitation, post-termination cooperation, non-disclosure, confidentiality, non-disparagement, non-solicitation and/or non-competition provisions. 
 “Separation
Benefits” means the continuing medical, dental and Basic Life Insurance benefits described in this Plan in the sections entitled Continuation of Medical and Dental Benefits and Continuation of Life Insurance Benefits. 

“Separation Date” means the Eligible Employee’s last day of employment with the Employer due to a Qualifying Termination. 

“Separation Pay” means the cash benefit payable under this Plan as described in the section entitled Separation Pay Schedule.

 “Separation Plan Benefits” means, collectively, Separation Pay, Separation Benefits and Outplacement Benefits. 

  

					
	 Organon
 Executive Severance Program
	  	17	  	Effective: June 2, 2021

 Exhibit A 

Base Salary Separation Pay 

(For Eligible Employees Previously Employed with Merck & Co., Inc.) 

 

			
	 Complete Years of Continuous Service at
Separation Date
	  	 Amount of Base Salary Separation Pay in Weeks (Annual Base
Salary
Divided by 52)

	0	  	26
	1	  	40
	2	  	40
	3	  	40
	4	  	40
	5	  	42
	6	  	44
	7	  	46
	8	  	48
	9	  	50
	10	  	52
	11	  	54
	12	  	56
	13	  	58
	14	  	60
	15	  	62
	16	  	64
	17	  	66
	18	  	68
	19	  	70
	20	  	72
	21	  	74
	22	  	76
	23+	  	78

  

					
	 Organon
 Executive Severance Program
	  	18	  	Effective: June 2, 2021Exhibit 4.4 

 

WARRANT AGREEMENT

 

between

FINTECH ACQUISITION CORP. VI

and

CONTINENTAL STOCK TRANSFER & TRUST COMPANY

 

Dated , 2021

 

THIS WARRANT AGREEMENT (this “Agreement”),
dated as of , 2021, is by and between FinTech Acquisition Corp. VI, a Delaware corporation (the “Company”),
and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (in such capacity,
the “Warrant Agent”, also referred to herein as the “Transfer Agent”).

 

WHEREAS, the Company has entered into those certain
Unit Subscription Agreements, dated , 2021, with each of FinTech Investor Holdings VI, LLC, a Delaware limited liability company (together
with FinTech Masala Advisors VI, LLC, the “Sponsor”) and Cantor Fitzgerald & Co., a New York general partnership
(“Cantor”), pursuant to which the Sponsor and Cantor will purchase an aggregate of 690,000 Units (as defined
below) for a purchase price of $6,900,000 (“Placement Units”), each Unit consisting of one share of Common Stock
(as defined below) (“Placement Shares”) and one-fourth of one warrant to purchase one Placement Share (the “Placement
Warrants”) of the Company, and, in connection therewith, has determined to issue and deliver up to 172,500 Placement Warrants
bearing the legend set forth in Exhibit B hereto, to be sold simultaneously with the closing of the Offering (as defined below). 
Each Placement Warrant entitles the holder thereof to purchase one Placement Share at a price of $11.50 per share, subject to adjustment
as described herein; and

 

WHEREAS, in order to finance the Company’s
transaction costs in connection with an intended initial merger, share exchange, asset acquisition, share purchase, reorganization or
similar business combination, involving the Company and one or more businesses (a “Business Combination”), the
Sponsor or an affiliate of the Sponsor or certain of the Company’s officers or directors may, but are not obligated to, loan the
Company funds as the Company may require, of which up to $2,000,000 of such loans may be convertible into Units at a price of $10.00 per
Unit, each Unit consisting of one share of Common Stock and one-fourth of one warrant to purchase one share of Common Stock (the “Loan
Warrants”); and

 

WHEREAS, the Company is engaged in an initial public
offering (the “Offering”) of units of the Company’s equity securities, each such unit comprised of one
share of Common Stock and one-fourth of one Public Warrant (as defined below) (the “Public Units”, and together
with the Placement Units, the “Units”) and, in connection therewith, has determined to issue and deliver up
to 6,325,000 redeemable warrants (including up to 825,000 redeemable warrants subject to the Over-allotment Option) to public investors
in the Offering (the “Public Warrants” and, together with the Placement Warrants and the Loan Warrants, the
“Warrants”).  Each whole Warrant entitles the holder thereof to purchase one share of Class A common stock
of the Company, par value $0.0001 per share (the “Common Stock”), for $11.50 per share, subject to adjustment
as described herein.  Only whole Warrants are exercisable.  A holder of the Public Warrants will not be able to exercise any
fraction of a Warrant; and

 

WHEREAS, the Company has filed with the Securities
and Exchange Commission (the “Commission”) a registration statement on Form S-1, No. 333-253422 (the
“Registration Statement”) and prospectus (the “Prospectus”), for the registration,
under the Securities Act of 1933, as amended (the “Securities Act”), of the Units, the Public Warrants and the
Common Stock included in the Units; and

 

WHEREAS, the Company desires the Warrant Agent
to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer,
exchange, redemption and exercise of the Warrants; and

 

     

     

    

 

WHEREAS, the Company desires to provide for the
form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of
rights, and immunities of the Company, the Warrant Agent and the holders of the Warrants; and

 

WHEREAS, all acts and things have been done and
performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant
Agent (if a physical certificate is issued), as provided herein, the valid, binding and legal obligations of the Company, and to authorize
the execution and delivery of this Agreement.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained,
the parties hereto agree as follows:

 

1. 
Appointment of Warrant Agent.  The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants,
and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth
in this Agreement.

 

2. 
Warrants.

 

2.1 
Form of Warrant.  Each Warrant shall initially be issued in registered form only.

 

2.2 
Effect of Countersignature.  If a physical certificate is issued, unless and until countersigned by the Warrant Agent pursuant
to this Agreement, a certificated Warrant shall be invalid and of no effect and may not be exercised by the holder thereof.

 

2.3 
Registration.

 

2.3.1  Warrant
Register.  The Warrant Agent shall maintain books (the “Warrant Register”), for the registration of
original issuance and the registration of transfer of the Warrants.  Upon the initial issuance of the Warrants in book-entry form,
the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise
in accordance with instructions delivered to the Warrant Agent by the Company.  Ownership of beneficial interests in the Public Warrants
shall be shown on, and the transfer of such ownership shall be effected through, records maintained by institutions that have accounts
with The Depository Trust Company (the “Depositary”) (such institution, with respect to a Warrant in its account,
a “Participant”).

 

If the Depositary subsequently ceases to make its
book-entry settlement system available for the Public Warrants, the Company may instruct the Warrant Agent regarding making other arrangements
for book-entry settlement.  In the event that the Public Warrants are not eligible for, or it is no longer necessary to have the
Public Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depositary to deliver to the
Warrant Agent for cancellation each book-entry Public Warrant, and the Company shall instruct the Warrant Agent to deliver to the Depositary
definitive certificates in physical form evidencing such Warrants (“Definitive Warrant Certificates”) which
shall be in the form annexed hereto as Exhibit A.

 

Physical certificates, if issued, shall be signed
by, or bear the facsimile signature of, the Chairman of the Board, the President, Chief Executive Officer, Chief Financial Officer, Secretary
or other principal officer of the Company.  In the event the person whose facsimile signature has been placed upon any Warrant shall
have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the
same effect as if he or she had not ceased to be such at the date of issuance.

 

2.3.2  Registered
Holder.  Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”)
as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing
on any physical certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and
for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

    2

     

    

 

2.4 
Detachability of Warrants.  The Common Stock and Public Warrants comprising the Units shall begin separate trading on the
52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday,
on which banks in New York City are generally open for normal business (a “Business Day”), then on the immediately
succeeding Business Day following such date, or earlier (the “Detachment Date”) with the consent of Cantor,
acting as representative of the several underwriters, but in no event shall the Common Stock and the Public Warrants comprising the Units
be separately traded until (A) the Company has filed a Current Report on Form 8-K with the Commission containing an audited
balance sheet reflecting the receipt by the Company of the gross proceeds of the Offering, including the proceeds then received by the
Company from the exercise by the underwriters of their right to purchase additional Units in the Offering (the “Over-allotment
Option”), if the Over-allotment Option is exercised prior to the filing of the Form 8-K, and (B) the Company issues
a press release announcing when such separate trading shall begin.

 

2.5 
Fractional Warrants.  The Company shall not issue fractional Warrants other than as part of the Units, each of which is comprised
of one share of Common Stock and one-fourth of one whole Public Warrant.  If, upon the detachment of Public Warrants from the Units
or otherwise, a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down to the nearest whole
number the number of Warrants to be issued to such holder.

 

2.6 
Placement Warrants; Loan Warrants.

 

2.6.1  The Placement
Warrants and the Loan Warrants shall be identical to the Public Warrants, except that so long as they are held by the Sponsor, Cantor
or any of their Permitted Transferees (as defined below) the Placement Warrants and the Loan Warrants:  (i) may be exercised
for cash or on a “cashless basis,” pursuant to subsection 3.3.1(c) hereof, (ii) including the Common Stock
issuable upon exercise of the Placement Warrants and the Loan Warrants, may not be transferred, assigned or sold until thirty (30) days
after the completion by the Company of an initial Business Combination, (iii) shall not be redeemable by the Company pursuant to
Section 6.1 hereof and (iv) shall only be redeemable by the Company pursuant to Section 6.2 if the Reference
Value (as defined below) is less than $18.00 per share (subject to adjustment in compliance with Section 4 hereof); provided,
however, that in the case of clause (ii), the Placement Warrants and the Loan Warrants and any Common Stock held by the Sponsor,
Cantor or any of their Permitted Transferees that are issued upon exercise of the Placement Warrants and the Loan Warrants may be transferred
by the holders thereof:

 

(a) 
to the Sponsor, the Company’s officers or directors, Cantor or Cantor’s officers, directors or direct or indirect equityholders,
any affiliates or family members of any of the Company’s officers, directors and Cantor, any members or partners of the Sponsor,
Cantor or their affiliates, any affiliates of the Sponsor, Cantor or any employees of such affiliates;

 

(b) 
in the case of an individual, by gift to a member of the individual’s immediate family, or to a trust, the beneficiary of which
is a member of one of the individual’s immediate family, or an affiliate of such person, or to a charitable organization;

 

(c) 
in the case of an individual, by virtue of laws of descent and distribution upon death of the individual;

 

(d) 
in the case of an individual, pursuant to a qualified domestic relations order;

 

(e) 
by private sales or transfers made in connection with the completion of the Company’s Business Combination at prices no greater
than the price at which the securities, were originally purchased;

 

(f) 
by virtue of the laws of Delaware, pursuant to the Sponsor’s organizational documents upon liquidation or dissolution of our Sponsor,
or pursuant to the organizational documents of Cantor upon liquidation or dissolution of Cantor;

 

(g) 
to the Company for no value for cancellation in connection with the completion of its initial Business Combination;

 

    3

     

    

 

(h) 
in the event of the Company’s liquidation prior to the Company’s completion of its initial Business Combination; or

 

(i) 
in the event of the Company’s completion of a liquidation, merger, stock exchange or other similar transaction which results in
all of the Company’s stockholders having the right to exchange their Common Stock for cash, securities or other property subsequent
to the completion of the Company’s initial Business Combination; or

 

provided, however, that in each case (except for clauses
(g), (h) or (i) or with the prior written consent of the Company) prior to such registration for transfer, the Warrant Agent
shall be presented with written documentation pursuant to which each permitted transferee (the “Permitted Transferees”)
must enter into a written agreement with the Company agreeing to be bound by these transfer restrictions.

 

3. 
Terms and Exercise of Warrants.

 

3.1 
Warrant Price.  Each whole Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant
and of this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $11.50 per share,
subject to the adjustments provided in Section 4 hereof and in the last sentence of this Section 3.1.  The
term “Warrant Price” as used in this Agreement shall mean the price per share (including in cash or by payment
of Warrants pursuant to a “cashless exercise,” to the extent permitted hereunder) described in the prior sentence at which
Common Stock may be purchased at the time a Warrant is exercised.  The Company in its sole discretion may lower the Warrant Price
at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days, provided that
the Company shall provide at least twenty (20) days prior written notice of such reduction to Registered Holders of the Warrants and,
provided further that any such reduction shall be identical among all of the Warrants.

 

3.2 
Duration of Warrants.  A Warrant may be exercised only during the period (the “Exercise Period”)
(A) commencing on the later of:  (i) the date that is thirty (30) days after the first date on which the Company completes
a Business Combination, and (ii) the date that is twelve (12) months from the date of the closing of the Offering, and (B) terminating
at the earliest to occur of (x) 5:00 p.m., New York City time on the date that is five (5) years after the date on which the
Company completes its initial Business Combination, (y) the liquidation of the Company in accordance with the Company’s governing
documents, if the Company fails to complete a Business Combination, and (z) other than with respect to the Placement Warrants and
the Loan Warrants then held by the Sponsor, Cantor or their Permitted Transferees with respect to a redemption pursuant to Section 6.1
hereof or, if the Reference Value equals or exceeds $18.00 per share (subject to adjustment in compliance with Section 4 hereof),
Section 6.2 hereof, 5:00 p.m., New York City time on the Redemption Date (as defined below) as provided in Section 6.3
hereof (the “Expiration Date”); provided, however, that the exercise of any Warrant shall be subject
to the satisfaction of any applicable conditions, as set forth in subsection 3.3.2 below, with respect to an effective registration
statement or a valid exemption therefrom being available.  Except with respect to the right to receive the Redemption Price (as defined
below) (other than with respect to a Placement Warrant or a Loan Warrant then held by the Sponsor, Cantor or their Permitted Transferees
in connection with a redemption pursuant to Section 6.1 hereof or, if the Reference Value equals or exceeds $18.00 per share
(subject to adjustment in compliance with Section 4 hereof), Section 6.2 hereof) in the event of a redemption (as set
forth in Section 6 hereof), each Warrant (other than a Placement Warrant or Loan Warrant then held by the Sponsor, Cantor
or their Permitted Transferees in the event of a redemption pursuant to Section 6.1 hereof or, if the Reference Value equals
or exceeds $18.00 per share (subject to adjustment in compliance with Section 4 hereof), Section 6.2 hereof) not exercised
on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall
cease at 5:00 p.m. New York City time on the Expiration Date.  The Company in its sole discretion may extend the duration of
the Warrants by delaying the Expiration Date; provided that the Company shall provide at least twenty (20) days prior written notice
of any such extension to Registered Holders of the Warrants and, provided further that any such extension shall be identical in
duration among all the Warrants. However, the period during which the Placement Warrants held by Cantor are exercisable may not be extended
(pursuant to the prior sentence or otherwise) beyond the date that is five years from the effective date of the Registration Statement. 

 

    4

     

    

 

3.3 
Exercise of Warrants.

 

3.3.1  Payment. 
Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the Registered Holder thereof by delivering
to the Warrant Agent at its corporate trust department (i) the Definitive Warrant Certificate evidencing the Warrants to be exercised,
or, in the case of a Warrant represented by a book-entry, the Warrants to be exercised (the “Book-Entry Warrants”)
on the records of the Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by the Warrant
Agent to the Depositary from time to time, (ii) an election to purchase (“Election to Purchase”) any Common
Stock pursuant to the exercise of a Warrant, properly completed and executed by the Registered Holder on the reverse of the Definitive
Warrant Certificate or, in the case of a Book-Entry Warrant, properly delivered by the Participant in accordance with the Depositary’s
procedures, and (iii) the payment in full of the Warrant Price for each Class A ordinary share as to which the Warrant is exercised
and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant for the Common Stock
and the issuance of such Common Stock, as follows:

 

(a) 
in lawful money of the United States, in good certified check or good bank draft payable to the order of the Warrant Agent;

 

(b) 
[Reserved];

 

(c) 
with respect to any Placement Warrant or Loan Warrant, so long as such Placement Warrant or Loan Warrant is held by the Sponsor, Cantor
or a Permitted Transferee, by surrendering the Warrants for that number of shares of Common Stock equal to (i) if in connection with
a redemption of Placement Warrants or Loan Warrants pursuant to Section 6.2 hereof, as provided in Section 6.2
hereof with respect to a Make-Whole Exercise and (ii) in all other scenarios the quotient obtained by dividing (x) the product
of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Sponsor Exercise Fair Market Value”
(as defined in this subsection 3.3.1(c)) less the Warrant Price by (y) the Sponsor Exercise Fair Market Value.  Solely
for purposes of this subsection 3.3.1(c), the “Sponsor Exercise Fair Market Value” shall mean the average last reported
sale price of the Common Stock for the ten (10) trading days ending on the third (3rd) trading day prior to the date on which notice
of exercise of the Warrant is sent to the Warrant Agent;

 

(d) 
on a cashless basis, as provided in Section 6.2 hereof with respect to a Make-Whole Exercise; or

 

(e) 
on a cashless basis, as provided in Section 7.4 hereof.

 

3.3.2  Issuance
of Common Stock on Exercise.  As soon as practicable after the exercise of any Warrant and the clearance of the funds in payment
of the Warrant Price (if payment is pursuant to subsection 3.3.1(a)), the Company shall issue to the Registered Holder of such
Warrant a book-entry position or certificate, as applicable, for the number of shares of Common Stock to which he, she or it is entitled,
registered in such name or names as may be directed by him, her or it on the register of members of the Company, and if such Warrant shall
not have been exercised in full, a new book-entry position or countersigned Warrant, as applicable, for the number of shares as to which
such Warrant shall not have been exercised.  Notwithstanding the foregoing, the Company shall not be obligated to deliver any Common
Stock pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a registration statement
under the Securities Act with respect to the Common Stock underlying the Public Warrants is then effective and a prospectus relating thereto
is current, subject to the Company’s satisfying its obligations under Section 7.4 or a valid exemption from registration
is available.  No Warrant shall be exercisable and the Company shall not be obligated to issue Common Stock upon exercise of a Warrant
unless the Common Stock issuable upon such Warrant exercise have been registered, qualified or deemed to be exempt from registration or
qualification under the securities laws of the state of residence of the Registered Holder of the Warrants.  Subject to Section 4.6
of this Agreement, a Registered Holder of Warrants may exercise its Warrants only for a whole number of shares of Common Stock. 
The Company may require holders of Public Warrants to settle the Warrant on a “cashless basis” pursuant to Section 7.4. 
If, by reason of any exercise of Warrants on a “cashless basis”, the holder of any Warrant would be entitled, upon the exercise
of such Warrant, to receive a fractional interest in a share of Common Stock, the Company shall round down to the nearest whole number,
the number of shares of Common Stock to be issued to such holder.

 

    5

     

    

 

3.3.3  Valid
Issuance.  All Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement and the governing
documents of the Company, shall be validly issued as fully paid and nonassessable.

 

3.3.4  Date
of Issuance.  Each person in whose name any book-entry position or certificate, as applicable, for Common Stock is issued and
who is registered in the register of members of the Company shall for all purposes be deemed to have become the holder of record of such
Common Stock on the date on which the Warrant, or book-entry position representing such Warrant, was surrendered and payment of the Warrant
Price was made, irrespective of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date
of such surrender and payment is a date when the register of members of the Company or book-entry system of the Warrant Agent are closed,
such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the
share transfer books or book-entry system are open.

 

3.3.5  Maximum
Percentage.  A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions contained
in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she
or it makes such election.  If the election is made by a holder, the Warrant Agent shall not effect the exercise of the holder’s
Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such
person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess
of 4.8% or 9.8% (the “Maximum Percentage”) of the Common Stock outstanding immediately after giving effect to
such exercise.  For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such
person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which
the determination of such sentence is being made, but shall exclude Common Stock that would be issuable upon (x) exercise of the
remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion
of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates
(including, without limitation, any convertible notes or convertible preferred shares or warrants) subject to a limitation on conversion
or exercise analogous to the limitation contained herein.  Except as set forth in the preceding sentence, for purposes of this paragraph,
beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”).  For purposes of the Warrant, in determining the number of outstanding shares of
Common Stock, the holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most
recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with
the Commission as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company
or Continental Stock Transfer & Trust Company, as transfer agent (in such capacity, the “Transfer Agent”),
setting forth the number of shares of Common Stock outstanding.  For any reason at any time, upon the written request of the holder
of the Warrant, the Company shall, within two (2) Business Days, confirm orally and in writing to such holder the number of shares
of Common Stock then outstanding.  In any case, the number of issued and outstanding shares of Common Stock shall be determined after
giving effect to the conversion or exercise of equity securities of the Company by the holder and its affiliates since the date as of
which such number of issued and outstanding shares of Common Stock was reported.  By written notice to the Company, the holder of
a Warrant may from time to time increase or decrease the Maximum Percentage applicable to such holder to any other percentage specified
in such notice; provided, however, that any such increase shall not be effective until the sixty-first (61st) day after
such notice is delivered to the Company.

 

    6

     

    

 

4. 
Adjustments.

 

4.1 
Share Capitalizations.

 

4.1.1  Sub-Divisions. 
If after the date hereof, and subject to the provisions of Section 4.6 below, the number of issued and outstanding shares
of Common Stock is increased by a share capitalization, or by a sub-division of Common Stock or other similar event, then, on the effective
date of such share capitalization, sub-division or similar event, the number of shares of Common Stock issuable on exercise of each Warrant
shall be increased in proportion to such increase in the issued and outstanding shares of Common Stock.  A rights offering to holders
of Common Stock entitling holders to purchase Common Stock at a price less than the “Historical Fair Market Value” (as defined
below) shall be deemed a capitalization of a number of shares of Common Stock equal to the product of (i) the number of shares of
Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are
convertible into or exercisable for shares of Common Stock) multiplied by (ii) one (1) minus the quotient of (x) the price
per share of Common Stock paid in such rights offering divided by (y) the Historical Fair Market Value.  For purposes of this
subsection 4.1.1, (i) if the rights offering is for securities convertible into or exercisable for Common Stock, in determining
the price payable for Common Stock, there shall be taken into account any consideration received for such rights, as well as any additional
amount payable upon exercise or conversion and (ii) “Historical Fair Market Value” means the volume weighted average
price of the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the first date on
which the Common Stock trades on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. 
No shares of Common Stock shall be issued at less than their par value.

 

4.1.2  Extraordinary
Dividends.  If the Company, at any time while the Warrants are outstanding and unexpired, shall pay a dividend or make a distribution
in cash, securities or other assets to the holders of Common Stock on account of such Common Stock (or other shares into which the Warrants
are convertible), other than (a) as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below),
(c) to satisfy the redemption rights of the holders of Common Stock in connection with a proposed initial Business Combination, (d) to
satisfy the redemption rights of the holders of Common Stock in connection with a stockholder vote to amend the Company’s amended
and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to allow redemption in connection
with the Company’s initial Business Combination or to redeem 100% of the Company’s public shares if the Company does not complete
its initial Business Combination within the time period required by the Company’s amended and restated certificate of incorporation,
as amended from time to time, (e) as a result of the repurchase of Common Stock by the Company if a proposed initial Business Combination
is presented to the stockholders of the Company for approval or (f) in connection with the redemption of public shares upon the failure
of the Company to complete its initial Business Combination and any subsequent distribution of its assets upon its liquidation (any such
non-excluded event being referred to herein as an “Extraordinary Dividend”), then the Warrant Price shall be
decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the fair market
value (as determined by the Company’s board of directors (the “Board”), in good faith) of any securities
or other assets paid on each share of Common Stock in respect of such Extraordinary Dividend.  For purposes of this subsection
4.1.2, “Ordinary Cash Dividends” means any cash dividend or cash distribution which, when combined on a
per share basis, with the per share amounts of all other cash dividends and cash distributions paid on Common Stock during the 365-day
period ending on the date of declaration of such dividend or distribution (as adjusted to appropriately reflect any of the events referred
to in other subsections of this Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the
Warrant Price or to the number of shares of Common Stock issuable on exercise of each Warrant) to the extent it does not exceed $0.50
(being 5% of the offering price of the Units in the Offering).

 

4.2 
Aggregation of Shares.  If after the date hereof, and subject to the provisions of Section 4.6 hereof, the number
of issued and outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification
of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split,
reclassification or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be decreased in proportion
to such decrease in issued and outstanding shares of Common Stock.

 

4.3 
Adjustments in Exercise Price.  Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants
is adjusted, as provided in subsection 4.1.1 or Section 4.2 above, the Warrant Price shall be adjusted (to the nearest
cent) by multiplying such Warrant Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be the
number of shares of Common Stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the
denominator of which shall be the number of shares of Common Stock so purchasable immediately thereafter.

 

    7

     

    

 

4.4 
Raising of Capital in Connection with the Initial Business Combination.  If (x) the Company issues additional shares
of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination
at an issue price or effective issue price of less than $9.20 per share of Common Stock (with such issue price or effective issue price
to be determined in good faith by the Board and, in the case of any such issuance to the Sponsor or their affiliates, without taking into
account any shares of Class B common stock of the Company, par value $0.0001 per share (the “Class B Common Stock”),
held by the Sponsor or such affiliates, as applicable, prior to such issuance (the “Newly Issued Price”), (y) the
aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for
the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business
Combination (net of redemptions), and (z) the volume-weighted average trading price of the Common Stock during the twenty (20) trading
day period starting on the trading day prior to the day on which the Company completes its initial Business Combination (such price, the
“Market Value”) is below $9.20 per share, the Warrant Price will be adjusted (to the nearest cent) to be equal
to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described
in Section 6.2 and Section 6.1, respectively, will be adjusted (to the nearest cent) to be equal to 100% and 180%,
respectively, of the higher of the Market Value and the Newly Issued Price.

 

4.5 
Replacement of Securities upon Reorganization, etc.  In case of any reclassification or reorganization of the issued
and outstanding Common Stock (other than a change under Section 4.1 or Section 4.2 hereof or that solely affects
the par value of such Common Stock), or in the case of any merger or consolidation of the Company with or into another corporation (other
than a consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification or
reorganization of the issued and outstanding Common Stock), or in the case of any sale or conveyance to another corporation or entity
of the assets or other property of the Company as an entirety or substantially as an entirety in connection with which the Company is
dissolved, the holders of the Warrants shall thereafter have the right to purchase and receive, upon the basis and upon the terms and
conditions specified in the Warrants and in lieu of the Common Stock of the Company immediately theretofore purchasable and receivable
upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including
cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or
transfer, that the holder of the Warrants would have received if such holder had exercised his, her or its Warrant(s) immediately
prior to such event (the “Alternative Issuance”); provided, however, that (i) if the holders
of the Common Stock were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable
upon such consolidation or merger, then the kind and amount of securities, cash or other assets constituting the Alternative Issuance
for which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount received per share by
the holders of the Common Stock in such consolidation or merger that affirmatively make such election, and (ii) if a tender, exchange
or redemption offer shall have been made to and accepted by the holders of the Common Stock (other than a tender, exchange or redemption
offer made by the Company in connection with redemption rights held by stockholders of the Company as provided for in the Company’s
governing documents or as a result of the repurchase of Common Stock by the Company if a proposed initial Business Combination is presented
to the stockholders of the Company for approval) under circumstances in which, upon completion of such tender or exchange offer, the maker
thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act) of which such maker
is a part, and together with any affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act) and
any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3
under the Exchange Act) more than 50% of the issued and outstanding Common Stock, the holder of a Warrant shall be entitled to receive
as the Alternative Issuance, the highest amount of cash, securities or other property to which such holder would actually have been entitled
as a stockholder if such Warrant holder had exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such
offer and all of the Common Stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments
(from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in
this Section 4; provided further that if less than 70% of the consideration receivable by the holders of the Common
Stock in the applicable event is payable in the form of shares in the successor entity that is listed for trading on a national securities
exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such
event, and if the Registered Holder properly exercises the Warrant within thirty (30) days following the public disclosure of the consummation
of such applicable event by the Company pursuant to a Current Report on Form 8-K filed with the Commission, the Warrant Price shall
be reduced by an amount (in dollars) equal to the difference of (i) the Warrant Price in effect prior to such reduction minus (ii) (A) the
Per Share Consideration (as defined below) (but in no event less than zero) minus (B) the Black-Scholes Warrant Value (as defined
below).  The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the consummation
of the applicable event based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets (assuming zero
dividends) (“Bloomberg”).  For purposes of calculating such amount, (i) Section 6 of this
Agreement shall be taken into account, (ii) the price of each share of Common Stock shall be the volume weighted average price of
the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the
applicable event, (iii) the assumed volatility shall be the 90 day volatility obtained from the HVT function on Bloomberg determined
as of the trading day immediately prior to the day of the announcement of the applicable event and (iv) the assumed risk-free interest
rate shall correspond to the U.S. Treasury rate for a period equal to the remaining term of the Warrant. “Per Share Consideration”
means (i) if the consideration paid to holders of the Common Stock consists exclusively of cash, the amount of such cash per share
of Common Stock, and (ii) in all other cases, the volume weighted average price of the Common Stock as reported during the ten (10) trading
day period ending on the trading day prior to the effective date of the applicable event.  If any reclassification or reorganization
also results in a change in Common Stock covered by subsection 4.1.1, then such adjustment shall be made pursuant to subsection
4.1.1 or Sections 4.2, 4.3 and this Section 4.4.  The provisions of this Section 4.4 shall
similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers.  In no event
will the Warrant Price be reduced to less than the par value per share issuable upon exercise of such Warrant.

 

    8

     

    

 

4.6 
Notices of Changes in Warrant.  Upon every adjustment of the Warrant Price or the number of shares issuable upon exercise
of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting
from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a Warrant,
setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.  Upon the occurrence
of any event specified in Sections 4.1, 4.2, 4.3, 4.4 or 4.5, the Company shall give written notice
of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register, of
the record date or the effective date of the event.  Failure to give such notice, or any defect therein, shall not affect the legality
or validity of such event.

 

4.7 
No Fractional Shares.  Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue
fractional shares upon the exercise of Warrants.  If, by reason of any adjustment made pursuant to this Section 4, the
holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall,
upon such exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to such holder.

 

4.8 
Form of Warrant.  The form of Warrant need not be changed because of any adjustment pursuant to this Section 4,
and Warrants issued after such adjustment may state the same Warrant Price and the same number of shares as is stated in the Warrants
initially issued pursuant to this Agreement; provided, however, that the Company may at any time in its sole discretion
make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant
thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as
so changed.

 

4.9 
Other Events.  In case any event shall occur affecting the Company as to which none of the provisions of the preceding subsections
of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to
(i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then,
in each such case, the Company shall appoint a firm of independent registered public accountants, investment banking or other appraisal
firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented by the
Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine that an adjustment is
necessary, the terms of such adjustment; provided, however, that under no circumstances shall the Warrants be adjusted pursuant
to this Section 4.9 as a result of any issuance of securities in connection with a Business Combination.  The Company
shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion.

 

4.10 
No Adjustment.  For the avoidance of doubt, no adjustment shall be made to the terms of the Warrants solely as a result of
an adjustment to the conversion ratio of the Class B Common Stock into shares of Common Stock or the conversion of the Class B
Common Stock into shares of Common Stock, in each case, pursuant to the Company’s amended and restated certificate of incorporation,
as amended from time to time.

 

    9

     

    

 

5. 
Transfer and Exchange of Warrants.

 

5.1 
Registration of Transfer.  The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon
the Warrant Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied
by appropriate instructions for transfer.  Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants
shall be issued and the old Warrant shall be cancelled by the Warrant Agent.  In the case of certificated Warrants, the Warrants
so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon request.

 

5.2 
Procedure for Surrender of Warrants.  Warrants may be surrendered to the Warrant Agent, together with a written request for
exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered
Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that except
as otherwise provided herein or with respect to any Book-Entry Warrant, each Book-Entry Warrant may be transferred only in whole and only
to the Depositary, to another nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; provided
further, however that in the event that a Warrant surrendered for transfer bears a restrictive legend (as in the case of the
Placement Warrants and the Loan Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof
until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether
the new Warrants must also bear a restrictive legend.

 

5.3 
Fractional Warrants.  The Warrant Agent shall not be required to effect any registration of transfer or exchange which shall
result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as part of the Units.

 

5.4 
Service Charges.  No service charge shall be made for any exchange or registration of transfer of Warrants.

 

5.5 
Warrant Execution and Countersignature.  The Warrant Agent is hereby authorized to countersign and to deliver, in accordance
with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the
Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf of the Company for
such purpose.

 

5.6 
Transfer of Warrants.  Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only together with
the Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such
Unit.  Furthermore, each transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants included
in such Unit.  Notwithstanding the foregoing, the provisions of this Section 5.6 shall have no effect on any transfer
of Warrants on and after the Detachment Date.

 

6. 
Redemption.

 

6.1 
Redemption of Warrants When the Price per Share of Common Stock Equals or Exceeds $18.00.  Subject to Section 6.5
hereof, not less than all of the outstanding Warrants may be redeemed, at the option of the Company, at any time during the Exercise Period,
at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below,
at a Redemption Price of $0.01 per Warrant, provided that (a) the Reference Value (as defined below) equals or exceeds $18.00
per share (subject to adjustment in compliance with Section 4 hereof) and (b) there is an effective registration statement
covering the Common Stock issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout the
30-day Redemption Period (as defined in Section 6.3 below).

 

    10

     

    

 

6.2 
Redemption of Warrants When the Price per Share of Common Stock Equals or Exceeds $10.00.  Subject to Section 6.5
hereof, not less than all of the outstanding Warrants may be redeemed, at the option of the Company, at any time during the Exercise Period,
at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below,
at a Redemption Price of $0.10 per Warrant, provided that (i) the Reference Value equals or exceeds $10.00 per share (subject
to adjustment in compliance with Section 4 hereof) and (ii) if the Reference Value is less than $18.00 per share (subject
to adjustment in compliance with Section 4 hereof), the Placement Warrants and the Loan Warrants are also concurrently called
for redemption on the same terms as the outstanding Public Warrants.  During the 30-day Redemption Period in connection with a redemption
pursuant to this Section 6.2, Registered Holders of the Warrants may elect to exercise their Warrants on a “cashless
basis” pursuant to subsection 3.3.1 and receive a number of shares of Common Stock determined by reference to the table below,
based on the Redemption Date (calculated for purposes of the table as the period to expiration of the Warrants) and the “Redemption
Fair Market Value” (as such term is defined in this Section 6.2) (a “Make-Whole Exercise”). 
Solely for purposes of this Section 6.2, the “Redemption Fair Market Value” shall mean the volume weighted average
price of the Common Stock for the ten (10) trading days immediately following the date on which notice of redemption pursuant to
this Section 6.2 is sent to the Registered Holders.  In connection with any redemption pursuant to this Section 6.2,
the Company shall provide the Registered Holders with the Redemption Fair Market Value no later than one (1) Business Day after the
ten (10) trading day period described above ends.

 

	Redemption Date	 	Redemption Fair Market Value of Common Stock	 
	(period to
 expiration
 of warrants)	 	<10.00	 	 	11.00	 	 	12.00	 	 	13.00	 	 	14.00	 	 	15.00	 	 	16.00	 	 	17.00	 	 	>18.00	 
	60 months	 	 	0.261	 	 	 	0.280	 	 	 	0.297	 	 	 	0.311	 	 	 	0.324	 	 	 	0.337	 	 	 	0.348	 	 	 	0.358	 	 	 	0.361	 
	57 months	 	 	0.257	 	 	 	0.277	 	 	 	0.294	 	 	 	0.310	 	 	 	0.324	 	 	 	0.337	 	 	 	0.348	 	 	 	0.358	 	 	 	0.361	 
	54 months	 	 	0.252	 	 	 	0.272	 	 	 	0.291	 	 	 	0.307	 	 	 	0.322	 	 	 	0.335	 	 	 	0.347	 	 	 	0.357	 	 	 	0.361	 
	51 months	 	 	0.246	 	 	 	0.268	 	 	 	0.287	 	 	 	0.304	 	 	 	0.320	 	 	 	0.333	 	 	 	0.346	 	 	 	0.357	 	 	 	0.361	 
	48 months	 	 	0.241	 	 	 	0.263	 	 	 	0.283	 	 	 	0.301	 	 	 	0.317	 	 	 	0.332	 	 	 	0.344	 	 	 	0.356	 	 	 	0.361	 
	45 months	 	 	0.235	 	 	 	0.258	 	 	 	0.279	 	 	 	0.298	 	 	 	0.315	 	 	 	0.330	 	 	 	0.343	 	 	 	0.356	 	 	 	0.361	 
	42 months	 	 	0.228	 	 	 	0.252	 	 	 	0.274	 	 	 	0.294	 	 	 	0.312	 	 	 	0.328	 	 	 	0.342	 	 	 	0.355	 	 	 	0.361	 
	39 months	 	 	0.221	 	 	 	0.246	 	 	 	0.269	 	 	 	0.290	 	 	 	0.309	 	 	 	0.325	 	 	 	0.340	 	 	 	0.354	 	 	 	0.361	 
	36 months	 	 	0.213	 	 	 	0.239	 	 	 	0.263	 	 	 	0.285	 	 	 	0.305	 	 	 	0.323	 	 	 	0.339	 	 	 	0.353	 	 	 	0.361	 
	33 months	 	 	0.205	 	 	 	0.232	 	 	 	0.257	 	 	 	0.280	 	 	 	0.301	 	 	 	0.320	 	 	 	0.337	 	 	 	0.352	 	 	 	0.361	 
	30 months	 	 	0.196	 	 	 	0.224	 	 	 	0.250	 	 	 	0.274	 	 	 	0.297	 	 	 	0.316	 	 	 	0.335	 	 	 	0.351	 	 	 	0.361	 
	27 months	 	 	0.185	 	 	 	0.214	 	 	 	0.242	 	 	 	0.268	 	 	 	0.291	 	 	 	0.313	 	 	 	0.332	 	 	 	0.350	 	 	 	0.361	 
	24 months	 	 	0.173	 	 	 	0.204	 	 	 	0.233	 	 	 	0.260	 	 	 	0.285	 	 	 	0.308	 	 	 	0.329	 	 	 	0.348	 	 	 	0.361	 
	21 months	 	 	0.161	 	 	 	0.193	 	 	 	0.223	 	 	 	0.252	 	 	 	0.279	 	 	 	0.304	 	 	 	0.326	 	 	 	0.347	 	 	 	0.361	 
	18 months	 	 	0.146	 	 	 	0.179	 	 	 	0.211	 	 	 	0.242	 	 	 	0.271	 	 	 	0.298	 	 	 	0.322	 	 	 	0.345	 	 	 	0.361	 
	15 months	 	 	0.130	 	 	 	0.164	 	 	 	0.197	 	 	 	0.230	 	 	 	0.262	 	 	 	0.291	 	 	 	0.317	 	 	 	0.342	 	 	 	0.361	 
	12 months	 	 	0.111	 	 	 	0.146	 	 	 	0.181	 	 	 	0.216	 	 	 	0.250	 	 	 	0.282	 	 	 	0.312	 	 	 	0.339	 	 	 	0.361	 
	9 months	 	 	0.090	 	 	 	0.125	 	 	 	0.162	 	 	 	0.199	 	 	 	0.237	 	 	 	0.272	 	 	 	0.305	 	 	 	0.336	 	 	 	0.361	 
	6 months	 	 	0.065	 	 	 	0.099	 	 	 	0.137	 	 	 	0.178	 	 	 	0.219	 	 	 	0.259	 	 	 	0.296	 	 	 	0.331	 	 	 	0.361	 
	3 months	 	 	0.034	 	 	 	0.065	 	 	 	0.104	 	 	 	0.150	 	 	 	0.197	 	 	 	0.243	 	 	 	0.286	 	 	 	0.326	 	 	 	0.361	 
	0 months	 	 	—	 	 	 	—	 	 	 	0.042	 	 	 	0.115	 	 	 	0.179	 	 	 	0.233	 	 	 	0.281	 	 	 	0.323	 	 	 	0.361	 

 

The exact Redemption Fair Market Value and Redemption
Date may not be set forth in the table above, in which case, if the Redemption Fair Market Value is between two values in the table or
the Redemption Date is between two redemption dates in the table, the number of shares of Common Stock to be issued for each Warrant exercised
in a Make-Whole Exercise will be determined by a straight-line interpolation between the number of shares set forth for the higher and
lower Redemption Fair Market Values and the earlier and later redemption dates, as applicable, based on a 365- or 366-day year, as applicable.

 

The share prices set forth in the column headings
of the table above shall be adjusted as of any date on which the number of shares issuable upon exercise of a Warrant or the Warrant Price
is adjusted pursuant to Section 4 hereof.  In the event of a Warrant Price adjustment pursuant to Section 4.3,
the adjusted share prices in the column headings shall equal the share prices immediately prior to such adjustment, multiplied by a fraction,
the numerator of which is the Warrant Price immediately prior to such adjustment and the denominator of which is the Warrant Price immediately
after such adjustment.  In such an event, the number of shares in the table above shall be adjusted by multiplying such share amounts
by a fraction, the numerator of which is the number of shares deliverable upon exercise of a Warrant immediately prior to such adjustment
and the denominator of which is the number of shares deliverable upon exercise of a Warrant as so adjusted. If the Warrant Price is adjusted
pursuant to Section 4.4, the adjusted share prices set forth in the column headings of the table above shall be multiplied by a
fraction, the numerator of which is the higher of the Market Value and the Newly Issued Price and the denominator of which is $10.00. 
In no event will the number of shares issued in connection with a Make-Whole Exercise exceed 0.361 shares of Common Stock per Warrant
(subject to adjustment).

 

    11

     

    

 

6.3 
Date Fixed for, and Notice of, Redemption; Redemption Price; Reference Value.  In the event that the Company elects to redeem
the Warrants pursuant to Sections 6.1 or 6.2, the Company shall fix a date for the redemption (the “Redemption
Date”).  Notice of redemption shall be mailed by first class mail, postage prepaid, by the Company not less than thirty
(30) days prior to the Redemption Date (the “30-day Redemption Period”) to the Registered Holders of the Warrants
to be redeemed at their last addresses as they shall appear on the registration books.  Any notice mailed in the manner herein provided
shall be conclusively presumed to have been duly given whether or not the Registered Holder received such notice.  As used in this
Agreement, (a) “Redemption Price” shall mean the price per Warrant at which any Warrants are redeemed pursuant
to Sections 6.1 or 6.2 and (b) “Reference Value” shall mean the last reported sales price
of the Common Stock for any twenty (20) trading days within the thirty (30) trading-day period ending on the third trading day prior to
the date on which notice of the redemption is given.

 

6.4 
Exercise After Notice of Redemption.  The Warrants may be exercised, for cash (or on a “cashless basis” in accordance
with Section 6.2 of this Agreement) at any time after notice of redemption shall have been given by the Company pursuant to
Section 6.3 hereof and prior to the Redemption Date.  On and after the Redemption Date, the record holder of the Warrants
shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price.

 

6.5 
Exclusion of Placement Warrants and Loan Warrants.  The Company agrees that (a) the redemption rights provided in Section 6.1
hereof shall not apply to the Placement Warrants and Loan Warrants if at the time of the redemption such Placement Warrants or Loan Warrants
continue to be held by the Sponsor, Cantor or their Permitted Transferees and (b) if the Reference Value equals or exceeds $18.00
per share (subject to adjustment in compliance with Section 4 hereof), the redemption rights provided in Section 6.2
hereof shall not apply to the Placement Warrants or Loan Warrants if at the time of the redemption such Placement Warrants or Loan Warrants
continue to be held by the Sponsor, Cantor or their Permitted Transferees.  However, once such Placement Warrants or Loan Warrants
are transferred (other than to Permitted Transferees in accordance with Section 2.6 hereof), the Company may redeem the Placement
Warrants or Loan Warrants pursuant to Section 6.1 or 6.2 hereof, provided that the criteria for redemption are
met, including the opportunity of the holder of such Placement Warrants or Loan Warrants to exercise the Placement Warrants or Loan Warrants
prior to redemption pursuant to Section 6.4 hereof.  Placement Warrants or Loan Warrants that are transferred to persons
other than Permitted Transferees shall upon such transfer cease to be Placement Warrants or Loan Warrants and shall become Public Warrants
under this Agreement, including for purposes of Section 9.8 hereof.

 

7. 
Other Provisions Relating to Rights of Holders of Warrants.

 

7.1 
No Rights as Stockholder.  A Warrant does not entitle the Registered Holder thereof to any of the rights of a stockholder
of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights
to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of
the Company or any other matter.

 

7.2 
Lost, Stolen, Mutilated, or Destroyed Warrants.  If any Warrant is lost, stolen, mutilated, or destroyed, the Company and
the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a
mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen,
mutilated, or destroyed.  Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not
the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

 

7.3 
Reservation of Common Stock.  The Company shall at all times reserve and keep available a number of its authorized but unissued
shares of Common Stock that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 

    12

     

    

 

7.4 
Registration of Common Stock; Cashless Exercise at Company’s Option.

 

7.4.1 
Registration of the Common Stock.  The Company agrees that as soon as practicable, but in no event later than twenty (20)
Business Days after the closing of its initial Business Combination, it shall use its best efforts to file with the Commission a registration
statement for the registration, under the Securities Act, of the Common Stock issuable upon exercise of the Warrants.  The Company
shall use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and
a current prospectus relating thereto, until the expiration or redemption of the Warrants in accordance with the provisions of this Agreement. 
If any such registration statement has not been declared effective by the sixtieth (60th) Business Day following the closing of the Business
Combination, holders of the Warrants shall have the right, during the period beginning on the sixty-first (61st) Business Day after the
closing of the Business Combination and ending upon such registration statement being declared effective by the Commission, and during
any other period when the Company shall fail to have maintained an effective registration statement covering the issuance of the Common
Stock issuable upon exercise of the Warrants, to exercise such Warrants on a “cashless basis,” pursuant to subsection 3.3.1,
by exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act or another exemption) for that number of
shares of Common Stock equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of shares
of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) less the Warrant
Price by (y) the Fair Market Value and (B) 0.361.  Solely for purposes of this subsection 7.4.1, “Fair Market
Value” shall mean the volume-weighted average price of the Common Stock as reported during the ten (10) trading day period
ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the holder of such Warrants
or its securities broker or intermediary.  The date that notice of “cashless exercise” is received by the Warrant Agent
shall be conclusively determined by the Warrant Agent.  In connection with the “cashless exercise” of a Public Warrant,
the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm
with securities law experience) stating that (i) the exercise of the Warrants on a “cashless basis” in accordance with
this subsection 7.4.1 is not required to be registered under the Securities Act and (ii) the Common Stock issued upon such
exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate (as such term is defined
in Rule 144 under the Securities Act) of the Company and, accordingly, shall not be required to bear a restrictive legend. 
Except as provided in subsection 7.4.2, for the avoidance of doubt, unless and until all of the Warrants have been exercised or
have expired, the Company shall continue to be obligated to comply with its registration obligations under the first three sentences of
this subsection 7.4.1.

 

7.4.2 
Cashless Exercise at Company’s Option.  If the Common Stock is at the time of any exercise of a Public Warrant not listed
on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of
the Securities Act, the Company may, at its option, (i) require holders of Public Warrants who exercise Public Warrants to exercise
such Public Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act as described
in subsection 7.4.1 and (ii) in the event the Company so elects, the Company shall (x) not be required to file or maintain
in effect a registration statement for the registration, under the Securities Act, of the Common Stock issuable upon exercise of the Warrants,
notwithstanding anything in this Agreement to the contrary, and (y) use its commercially reasonable efforts to register or qualify
for sale the Common Stock issuable upon exercise of the Public Warrant under applicable blue sky laws of the state of the residence of
the holder to the extent an exemption is not available.

 

8. 
Concerning the Warrant Agent and Other Matters.

 

8.1 
Payment of Taxes.  The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the Company
or the Warrant Agent in respect of the issuance or delivery of Common Stock upon the exercise of the Warrants, but the Company shall not
be obligated to pay any transfer taxes in respect of the Warrants or such shares.

 

    13

     

    

 

8.2 
Resignation, Consolidation, or Merger of Warrant Agent.

 

8.2.1 
Appointment of Successor Warrant Agent.  The Warrant Agent, or any successor to it hereafter appointed, may resign its duties
and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. 
If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing
a successor Warrant Agent in place of the Warrant Agent.  If the Company shall fail to make such appointment within a period of thirty
(30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant (who
shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the
Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s
cost.  Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing
under the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State
of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or
state authority.  After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities,
duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any
further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver,
at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such
predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and
deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all
such authority, powers, rights, immunities, duties, and obligations.

 

8.2.2 
Notice of Successor Warrant Agent.  In the event a successor Warrant Agent shall be appointed, the Company shall give notice
thereof to the predecessor Warrant Agent and the Transfer Agent for the Common Stock not later than the effective date of any such appointment.

 

8.2.3 
Merger or Consolidation of Warrant Agent.  Any corporation into which the Warrant Agent may be merged or with which it may
be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the
successor Warrant Agent under this Agreement without any further act.

 

8.3 
Fees and Expenses of Warrant Agent.

 

8.3.1 
Remuneration.  The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent
hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that
the Warrant Agent may reasonably incur in the execution of its duties hereunder.

 

8.3.2 
Further Assurances.  The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed,
acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant
Agent for the carrying out or performing of the provisions of this Agreement.

 

8.4 
Liability of Warrant Agent.

 

8.4.1 
Reliance on Company Statement.  Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem
it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved
and established by a statement signed by the Chairman of the Board, Chief Executive Officer, President or Chief Financial Officer of the
Company and delivered to the Warrant Agent.  The Warrant Agent may rely upon such statement for any action taken or suffered in good
faith by it pursuant to the provisions of this Agreement.

 

8.4.2 
Indemnity.  The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct, fraud or bad
faith.  The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments,
out-of-pocket costs and reasonable outside counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement,
except as a result of the Warrant Agent’s gross negligence, willful misconduct, fraud or bad faith.

 

    14

     

    

 

8.4.3 
Exclusions.  The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect
to the validity or execution of any Warrant (except its countersignature thereof).  The Warrant Agent shall not be responsible for
any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant.  The Warrant Agent shall not
be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method,
or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by
any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any Common Stock to be issued
pursuant to this Agreement or any Warrant or as to whether any Common Stock shall, when issued, be valid and fully paid and nonassessable.

 

8.5 
Acceptance of Agency.  The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the
same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants
exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of Common Stock
through the exercise of the Warrants.

 

8.6 
Waiver.  The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (“Claim”)
in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date
hereof, by and between the Company and Continental Stock Transfer & Trust Company as trustee thereunder) and hereby agrees not
to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever.  The
Warrant Agent hereby waives any and all Claims against the Trust Account and any and all rights to seek access to the Trust Account.

 

9. 
Miscellaneous Provisions.

 

9.1 
Successors.  All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent
shall bind and inure to the benefit of their respective successors and assigns.

 

9.2 
Notices.  Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the
holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by
certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another
address is filed in writing by the Company with the Warrant Agent), as follows:

 

FinTech Acquisition Corp. VI

2929 Arch Street, Suite 1703

Philadelphia, PA 19104

Attention:  James J. McEntee, III, President

Email:

 

with a copy (which shall not constitute service)
to:

 

Ledgewood, PC

Two Commerce Square

2001 Market Street, Suite 3400

Philadelphia PA 19103

Fax: 215-735-2513

Attention: Mark Rosenstein, Esq. 

 

Any notice, statement or demand authorized by this Agreement to be
given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be sufficiently given when so delivered
if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such
notice, postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with the Company), as follows:

 

Continental Stock Transfer & Trust Company

One State Street, 30th Floor

New York, NY 10004

Attention:  Compliance Department

 

    15

     

    

 

9.3 
Applicable Law.  The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in
all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application
of the substantive laws of another jurisdiction. 

 

9.4 
Persons Having Rights under this Agreement.  Nothing in this Agreement shall be construed to confer upon, or give to, any
person or corporation other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by
reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof.  All covenants, conditions, stipulations,
promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors
and assigns and of the Registered Holders of the Warrants.

 

9.5 
Examination of the Warrant Agreement.  A copy of this Agreement shall be available at all reasonable times at the office of
the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. 
The Warrant Agent may require any such holder to submit such holder’s Warrant for inspection by the Warrant Agent.

 

9.6 
Counterparts.  This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts
shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.
Delivery of a signed counterpart of this Agreement by facsimile or electronic transmission shall constitute valid and sufficient delivery
thereof.

 

9.7 
Effect of Headings.  The section headings herein are for convenience only and are not part of this Agreement and shall not
affect the interpretation thereof.

 

9.8 
Amendments.  This Agreement may be amended by the parties hereto without the consent of any Registered Holder (i) for the
purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing
any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable
and that the parties deem shall not adversely affect the interest of the Registered Holders and (ii) to make any amendments that are necessary
in the good faith determination of the Company’s board of directors (taking into account then existing market precedents) to allow
for the Warrants to be classified as equity in the Company’s financial statements.  All other modifications or amendments,
including any amendment to increase the Warrant Price or shorten the Exercise Period and any amendment to the terms of only the Placement
Warrants and/or the Loan Warrants, shall require the vote or written consent of the Registered Holders of 65% of the then outstanding
Public Warrants.  Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise Period
pursuant to Sections 3.1 and 3.2, respectively, or make any amendment necessary in the good faith determination of the Company’s
board of directors (taking into account then existing market precedents) to allow for the Warrants to be classified as equity in the Company’s
financial statements, in each case, without the consent of the Registered Holders.

 

9.9 
Severability.  This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof
shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof.  Furthermore, in lieu
of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement
a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

Exhibit A Form of Warrant Certificate

 

Exhibit B Legend — Placement Warrants and Loan Warrants

 

[SIGNATURE PAGE FOLLOWS]

 

    16

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be duly executed as of the date first above written.

 

	 	FINTECH ACQUISITION CORP. VI
	 	 
	 	By:	
	 	 	Name: James J. McEntee, III
	 	 	Title:   President and Secretary
	 	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY,
	 	as Warrant Agent
	 	 	 
	 	By:	
	 	 	Name: 
	 	 	Title: 
	 	 	 

  

 

[Signature Page to Warrant Agreement]

 

    17

     

    

 

EXHIBIT A

 

Form of Warrant Certificate

[FACE]

 

Number

 

Warrants

 

THIS WARRANT SHALL BE VOID IF NOT EXERCISED
PRIOR TO

THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR

IN THE WARRANT AGREEMENT DESCRIBED BELOW

 

FINTECH ACQUISITION CORP. VI

 

Incorporated Under the Laws of the State of
Delaware

 

CUSIP 31811H 114

 

Warrant Certificate

 

This Warrant Certificate certifies that
, or registered assigns, is the registered holder of warrant(s) evidenced hereby (the “Warrants” and each,
a “Warrant”) to purchase shares of Class A common stock, $0.0001 par value (the “Common Stock”),
of FinTech Acquisition Corp. VI, a Delaware corporation (the “Company”).  Each Warrant entitles the holder,
upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully
paid and non-assessable shares of Common Stock as set forth below, at the exercise price (the “Exercise Price”)
as determined pursuant to the Warrant Agreement, payable in lawful money (or through “cashless exercise” as
provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the Exercise
Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant Agreement. 
Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

 

Each whole Warrant is initially exercisable for
one fully paid and non-assessable share of Common Stock.  No fractional shares will be issued upon exercise of any Warrant. 
If, upon the exercise of Warrants, a holder would be entitled to receive a fractional interest in a share of Common Stock, the Company
will, upon exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to the Warrant holder. 
The number of shares of Common Stock issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events
as set forth in the Warrant Agreement.

 

The initial Exercise Price per one share of Common
Stock for any Warrant is equal to $11.50 per share.  The Exercise Price is subject to adjustment upon the occurrence of certain events
as set forth in the Warrant Agreement.

 

Subject to the conditions set forth in the Warrant
Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised by the end of such Exercise Period,
such Warrants shall become void.  The Warrants may be redeemed, subject to certain conditions, as set forth in the Warrant Agreement.

 

    A-1

     

    

 

Reference is hereby made to the further provisions
of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have the same effect as
though fully set forth at this place.

 

This Warrant Certificate shall not be valid unless
countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.

 

This Warrant Certificate shall be governed by and
construed in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof.

 

	 	FINTECH ACQUISITION CORP. VI
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY,
	 	as Warrant Agent
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    A-2

     

    

 

[Form of Warrant Certificate]

[Reverse]

 

The Warrants evidenced by this Warrant Certificate
are part of a duly authorized issue of Warrants entitling the holder on exercise to receive shares of Common Stock and are issued or to
be issued pursuant to a Warrant Agreement dated as of           ,
2021 (the “Warrant Agreement”), duly executed and delivered by the Company to Continental Stock Transfer &
Trust Company, a New York limited purpose trust company, as warrant agent (the “Warrant Agent”), which Warrant
Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the
rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and the holders (the words
“holders” or “holder” meaning the Registered Holders or Registered Holder, respectively)
of the Warrants.  A copy of the Warrant Agreement may be obtained by the holder hereof upon written request to the Company. 
Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

 

Warrants may be exercised at any time during the
Exercise Period set forth in the Warrant Agreement.  The holder of Warrants evidenced by this Warrant Certificate may exercise them
by surrendering this Warrant Certificate, with the form of Election to Purchase set forth hereon properly completed and executed, together
with payment of the Exercise Price as specified in the Warrant Agreement (or through “cashless exercise” as
provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent.  In the event that upon any
exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced hereby,
there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not
exercised.

 

Notwithstanding anything else in this Warrant Certificate
or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement covering the issuance
of the shares of Common Stock to be issued upon exercise is effective under the Securities Act and (ii) a prospectus thereunder relating
to the shares of Common Stock is current, except through “cashless exercise” as provided for in the Warrant
Agreement.

 

The Warrant Agreement provides that upon the occurrence
of certain events the number of shares of Common Stock issuable upon exercise of the Warrants set forth on the face hereof may, subject
to certain conditions, be adjusted.  If, upon exercise of a Warrant, the holder thereof would be entitled to receive a fractional
interest in a share of Common Stock, the Company shall, upon exercise, round down to the nearest whole number of shares of Common Stock
to be issued to the holder of the Warrant.

 

Warrant Certificates, when surrendered at the principal
corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by legal representative or attorney duly authorized
in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any
service charge, for another Warrant Certificate or Warrant Certificates of like tenor evidencing in the aggregate a like number of Warrants.

 

    A-3

     

    

 

Upon due presentation for registration of transfer
of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or Warrant Certificates of like tenor and evidencing
in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this Warrant Certificate, subject
to the limitations provided in the Warrant Agreement, without charge except for any tax or other governmental charge imposed in connection
therewith.

 

The Company and the Warrant Agent may deem and
treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation of
ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s) hereof,
and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.  Neither
the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a stockholder of the Company.

 

    A-4

     

    

 

Election to Purchase

(To Be Executed Upon Exercise of Warrant)

 

The undersigned hereby irrevocably elects to exercise
the right, represented by this Warrant Certificate, to receive shares of Common Stock and herewith tenders payment for such shares of
Common Stock to the order of FinTech Acquisition Corp. VI (the “Company”) in the amount of $          
 in accordance with the terms hereof.  The undersigned requests that a certificate for such shares of Common Stock
be registered in the name of           
, whose address is           
and that such shares of Common Stock be delivered to whose address is           
..  If said
number of shares of Common Stock is less than all of the shares of Common Stock purchasable hereunder, the undersigned requests that a
new Warrant Certificate representing the remaining balance of such shares of Common Stock be registered in the name of           
, whose address
is and that such Warrant Certificate be delivered to           
, whose address is           
..

 

In the event that the Warrant has been called for
redemption by the Company pursuant to Section 6.2 of the Warrant Agreement and a holder thereof elects to exercise its Warrant
pursuant to a Make-Whole Exercise, the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance
with subsection 3.3.1(c) or Section 6.2 of the Warrant Agreement, as applicable.

 

In the event that the Warrant is a Placement Warrant
or Loan Warrant that is to be exercised on a “cashless” basis pursuant to subsection 3.3.1(c) of the Warrant Agreement,
the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(c) of
the Warrant Agreement.

 

In the event that the Warrant is to be exercised
on a “cashless” basis pursuant to Section 7.4 of the Warrant Agreement, the number of shares of Common Stock that
this Warrant is exercisable for shall be determined in accordance with Section 7.4 of the Warrant Agreement.

 

In the event that the Warrant may be exercised,
to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of shares of Common Stock that this Warrant
is exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless
exercise and (ii) the holder hereof shall complete the following:  The undersigned hereby irrevocably elects to exercise the
right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive shares of
Common Stock.  If said number of shares is less than all of the shares of Common Stock purchasable hereunder (after giving effect
to the cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such shares of
Common Stock be registered in the name of  , whose address is 
          
and that such Warrant Certificate be delivered to            
, whose address is 
          
..

 

[Signature Page Follows]

 

    A-5

     

    

 

	Date:  , 20	 
	 	(Signature)
	 	 
	 	(Address)
	 	 
	 	 
	 	(Tax Identification Number)
	 	 
	Signature Guaranteed:	 
	 	 
	 	 	 
	 	 	 

 

THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN
ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE
GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED).

 

    A-6

     

    

 

EXHIBIT B

 

LEGEND

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD,
TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES
LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. 

 

IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS
ON TRANSFER DESCRIBED IN (1) THE LETTER AGREEMENT BY AND AMONG FINTECH ACQUISITION CORP. VI (THE “COMPANY”), THE OFFICERS
AND DIRECTORS OF THE COMPANY AND THE OTHER PARTIES THERETO, AND (2) THE PLACEMENT UNIT SUBSCRIPTION AGREEMENT BY AND BETWEEN THE COMPANY
AND CANTOR FITZGERALD & CO., THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE
THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3
OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2 OF THE WARRANT AGREEMENT)
WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

 

SECURITIES EVIDENCED BY THIS CERTIFICATE AND COMMON
STOCK OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT
TO BE EXECUTED BY THE COMPANY.

 

NO.                                       WARRANT

 

 

B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]